{"name":"QuantumLeap Healthcare Collaborative","slug":"quantumleap-healthcare-collaborative","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"Cemiplimab plus REGN3767","genericName":"Cemiplimab plus REGN3767","slug":"cemiplimab-plus-regn3767","indication":"Non-small cell lung cancer, PD-L1 ≥50%","status":"phase_2"},{"name":"AMG 386 and Trastuzumab","genericName":"AMG 386 and Trastuzumab","slug":"amg-386-and-trastuzumab","indication":"Locally advanced or metastatic breast cancer with HER2 overexpression","status":"phase_2"},{"name":"AMG 386 with or without Trastuzumab","genericName":"AMG 386 with or without Trastuzumab","slug":"amg-386-with-or-without-trastuzumab","indication":"Metastatic breast cancer, HER2-positive","status":"phase_2"},{"name":"Durvalumab plus Olaparib","genericName":"Durvalumab plus Olaparib","slug":"durvalumab-plus-olaparib","indication":"Urothelial carcinoma","status":"phase_2"},{"name":"Pembrolizumab - 8 cycle","genericName":"Pembrolizumab - 8 cycle","slug":"pembrolizumab-8-cycle","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"Pertuzumab and Trastuzumab","genericName":"Pertuzumab and Trastuzumab","slug":"pertuzumab-and-trastuzumab","indication":"HER2-positive metastatic breast cancer","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ALX148","genericName":"ALX148","slug":"alx148","indication":"Other","status":"phase_2"},{"name":"GSK 5733584","genericName":"GSK 5733584","slug":"gsk-5733584","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ALX148","genericName":"ALX148","slug":"alx148","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cemiplimab plus REGN3767","genericName":"Cemiplimab plus REGN3767","slug":"cemiplimab-plus-regn3767","phase":"phase_2","mechanism":"Cemiplimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, enhancing T-cell activation and immune response against tumor cells.","indications":["Non-small cell lung cancer, PD-L1 ≥50%","Cutaneous squamous cell carcinoma"],"catalyst":""},{"name":"AMG 386 and Trastuzumab","genericName":"AMG 386 and Trastuzumab","slug":"amg-386-and-trastuzumab","phase":"phase_2","mechanism":"AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing it from interacting with its receptor, thereby inhibiting angiogenesis. Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, which is overexpressed in certain cancer cells.","indications":["Locally advanced or metastatic breast cancer with HER2 overexpression","Locally advanced or metastatic gastric cancer with HER2 overexpression"],"catalyst":""},{"name":"AMG 386 with or without Trastuzumab","genericName":"AMG 386 with or without Trastuzumab","slug":"amg-386-with-or-without-trastuzumab","phase":"phase_2","mechanism":"AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing its interaction with its receptor, thereby inhibiting angiogenesis.","indications":["Metastatic breast cancer, HER2-positive"],"catalyst":""},{"name":"Durvalumab plus Olaparib","genericName":"Durvalumab plus Olaparib","slug":"durvalumab-plus-olaparib","phase":"phase_2","mechanism":"PD-1 inhibitor","indications":["Urothelial carcinoma","Breast cancer"],"catalyst":""},{"name":"GSK 5733584","genericName":"GSK 5733584","slug":"gsk-5733584","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pembrolizumab - 8 cycle","genericName":"Pembrolizumab - 8 cycle","slug":"pembrolizumab-8-cycle","phase":"phase_2","mechanism":"PD-1 inhibitor","indications":["Non-small cell lung cancer","Melanoma","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Pertuzumab and Trastuzumab","genericName":"Pertuzumab and Trastuzumab","slug":"pertuzumab-and-trastuzumab","phase":"marketed","mechanism":"Pertuzumab and trastuzumab are monoclonal antibodies that block HER2 signaling in cancer cells by binding to different epitopes of the HER2 receptor, preventing tumor growth and survival.","indications":["HER2-positive metastatic breast cancer","HER2-positive early-stage breast cancer (neoadjuvant and adjuvant settings)","HER2-positive gastric or gastroesophageal junction cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPa3lYbDRsUFRmNUh4RmtjeHFqQkd1OWJNcThfQUE5N0xLSHV5YmJQTmU3VmFLVVJzaElNem5KREtDbGtJckdrS0FPNDV1VWJPWnNpUUdyMm9hVXJQMHNVN0VDa2J4Z1BkcWNuY24yMnByeldwX1ZkREVJWE9fZEVWcU9CYw?oc=5","date":"2026-02-06","type":"regulatory","source":"Clinical Trials Arena","summary":"TransCode and Quantum Leap seek FDA approval for Phase IIa TTX-MC138 trial - Clinical Trials Arena","headline":"TransCode and Quantum Leap seek FDA approval for Phase IIa TTX-MC138 trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQZmFNaUhqVGYtN1pTNEhhSWFLazZwcktLVHVzYWJnMHdZLVI4MWJ6TmQ0REpHcU5MbGtFS2NZQXhaWEVMZkxqVDNVR0RfZGtTOFdtU0h3SjMyV3NBNFJKdlpuQ2pXa19vd2d6ZGxzSEhpU1ZtbWMweVFwZ1F2ano0XzRtaEYtX09sdEFKQnNfcFluUzdZMXVVZ3BtUmNFTTJCaFZHbVNyLWN6ZWwyNmhEQmJfNG5sVFNCcGZ5bVRuTHp4a3RDTEhVM01BWFR6ZkZiQ3pTbzQ1MGxjc1ZtZWM1eUpWaU5Yd2Nzbk9pYkZJMlRqSHNzZzJ5M1NkUDZqT3AzUEFyaFVn?oc=5","date":"2026-02-05","type":"trial","source":"PR Newswire","summary":"TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 - PR Newswire","headline":"TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138","sentiment":"negative"},{"url":"https://news.google.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?oc=5","date":"2026-01-12","type":"pipeline","source":"GlobeNewswire","summary":"Peptide Therapeutics Market Trends and Global Forecasts to - GlobeNewswire","headline":"Peptide Therapeutics Market Trends and Global Forecasts to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gJBVV95cUxPVVpUZVhuVXQxTkwxcDNJM1hZUHpQa2VxSlZTRXlHc0RWRFF4eDBZMWhPclY2U1RibUg0NXA4NGI5OEhSRDByeXN3TVhmaU4xaDl4V2E0TnpxU2NUYXNON1hUdmR2UDlNdzJmM282bFhhLUdjMXlDaGdQYThDV3h3aENZWUMtaFl2ajh1c0dQTi1uOTFVUW92c2VpM2JlVlVnSTZlNjVXejdleWRvVGV5R2RnTzl5NEVxOW9pdlJPcVhqWTBQZUtLdlJYc2NjeFhBeFBXTWdNVzY4Z2RzdzRXV19zYU1QVHo5Zm5wYlNqSjFlMHd4UG9wNEswS2p5LVdHcFhIQzBxZEczaUZYZHE1dlNSSldPZXQtSVdHeFJvYnJ6aGZfMEpudTR3VVhjNENVU3N0d1F2Q3VDM21ZekNrZEE0NmN1OXJIRGpKckZsX3Y3dw?oc=5","date":"2025-12-11","type":"trial","source":"PR Newswire","summary":"TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial - PR Newswire","headline":"TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, ","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-10-21","type":"trial","source":"PR Newswire","summary":"Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agen","headline":"Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Ess","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxObWpDeXJvMnd0WlNhRElweFh1Vi1FcERQTzB4QWF3S3VDMzRxQjJhSGwwSXk0OWFWNmJtdWpJVG1aWnJJNy1DX0V3X0R1a1RWOWx4ejNTWWNPc0NDOWFka3Y5VEJoaFYxb0k4Vmh6aldFTmtNXzFkcF9BbnYzekk0MVRJT3MyczIwdFBoSzFnT1BiWFl1NmpQbEVsNVJQMENlYkQzR3ViSQ?oc=5","date":"2025-06-10","type":"trial","source":"Clinical Leader","summary":"EHR-To-EDC Success In A Complex Oncology, Adaptive Platform Trial - Clinical Leader","headline":"EHR-To-EDC Success In A Complex Oncology, Adaptive Platform Trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxPam40Q29LNmVaUXNtbm1fSkpnb0s5QU9QXzhMdm8yWXVJcnNvek42YkVwUmhfTmFzSjAzY1c0YmpxZmtNSGpQOU9ZMldiNWxNZTFZelF6QnN3dnYzaTRKNjZNU0NxLWRPOTFvcjlrOFFzZDViblE5cGhXVmRLNkg4dnRTUms2bTFLc3EzaUJsNjJCcEk2UWFtWFd0aExlS2VRUEtXbHNYR1JlZkFJbmpjRjU1ZTBkME9lWkVyNHpxU3c2NGl5c01wU0xkVFlSME05aW0yaU5XYXI2RTA4aFg4ejEyNDVhUVM4SzItLUxSSnpzSFZpb25QeEJ2VmdnR2VuY0ZfQjFteHh0NEl5SllMSnRpYw?oc=5","date":"2025-03-20","type":"trial","source":"Business Wire","summary":"Evinova and Quantum Leap Healthcare Partner to Incorporate Real-Time Remote Patient Monitoring into Breast Cancer Platform Trial - Business Wire","headline":"Evinova and Quantum Leap Healthcare Partner to Incorporate Real-Time Remote Patient Monitoring into Breast Cancer Platfo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNU3JxSlJMU0ZlVnU5NXVzQjVKMzh1a241ZmhqdHJCcV9rclp3SWtDSWlhWXNseWhvMmxtSmNzbndnNWFRaW1nNnJ3T3hNeFM1RFdsSHFLTWFaYmJVcjFtT0dVQU1uV1F4eHBXdDdOWC1pYXFIQVBtWEI2Uk13aUFraTBuRDlieXRf?oc=5","date":"2024-01-15","type":"earnings","source":"BioSpace","summary":"Opinion: Healthcare Nonprofits Drive Positive Change for Patients - BioSpace","headline":"Opinion: Healthcare Nonprofits Drive Positive Change for Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOQkpqNDNuamN2NlFtaFJ5M01EREVWOHhGLXp6VWphNDJWRkcxYk1EenVCX2k5dXkzVEZyMk5WbXd6OG1OaEYzbVR0bVAzVVB1QU00NVBwM0t2NENmdld3LXllX1Vfb0hpZTh6ZWFPSGstQk1vM3dHRkxhcDQyR2xLVG43UC1YbV9WM1FNWDNmMEFGMzlETEZ3ai1qZVEzRUtzbFdNVWVyQQ?oc=5","date":"2021-06-25","type":"trial","source":"newsroom.wakehealth.edu","summary":"Wilkes Medical Center Joins Innovative COVID-19 Trial - newsroom.wakehealth.edu","headline":"Wilkes Medical Center Joins Innovative COVID-19 Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9VOUhtNFdRMHZDRUZSYW5va2x3UTlIQy1iOW01YXBmVWV2U193Y01DMkJoOWpJTTZBOHBTelJJX2Raem9VNWw4VVNZVWREakJBSGtRb1ZzYmZaZHJkM3VFSFZjbG9xUUdIVl8zMWQtd0xpc3VSbnFUZXh0NDU4ZlU?oc=5","date":"2020-08-09","type":"trial","source":"Applied Clinical Trials","summary":"Benefits of R&D Collaboration - Applied Clinical Trials","headline":"Benefits of R&D Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOdEdiYVJjZDVjX0pEX3dJM1cxZC12dWtsU0txcXc4d2FhdHdqT0I5eVo5ME05V21PTTdaNWh4MjRrTWdYMUxHa0QwT3VMX2tDSW9uWmJJcEtmV1RJRl81cVZlb1RjZW9aTXpQUDhIUGY1YXJ4R1lobExqYUI1NU8wZGl6TjVsczNlczhn?oc=5","date":"2020-08-03","type":"trial","source":"BioPharma Dive","summary":"Big pharma alliance recruits first patients for unusual COVID-19 study - BioPharma Dive","headline":"Big pharma alliance recruits first patients for unusual COVID-19 study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPRjVTaU91UzJqZGxmd1VKZllnRUwxUG9mTnBRbXlVQ2VNcE1OTGZMX0dGYzBNTzRoOUptUFJKRkRFU0M4dlpNam9LektGUjFkdnVER0pGTFVzY3RDY0E0ZFR4cjZxcTEycVQ2bk5ydzJDdEN2SzNpYjJVdlVyYl90b0dBRXVPc1FTdkFaUEVtOA?oc=5","date":"2018-09-12","type":"trial","source":"MultiVu","summary":"I-SPY 2, an Innovative Clinical Trial Model that is Revolutionizing the Treatment of Early Stage, High-Risk Breast Cancer - MultiVu","headline":"I-SPY 2, an Innovative Clinical Trial Model that is Revolutionizing the Treatment of Early Stage, High-Risk Breast Cance","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_2":7,"marketed":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}